These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 12558570

  • 21. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
    Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ.
    Epilepsia; 2009 Mar; 50(3):415-21. PubMed ID: 19054418
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A comparison of four antiepileptic drugs in status epilepticus: experience from India.
    Misra UK, Kalita J.
    Int J Neurosci; 2016 Nov; 126(11):1013-9. PubMed ID: 26456955
    [Abstract] [Full Text] [Related]

  • 26. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
    Stepanova D, Beran RG.
    Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
    Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG.
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
    [Abstract] [Full Text] [Related]

  • 30. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
    Markoula S, Chatzistefanidis D, Gatzonis S, Siatouni A, Siarava E, Verentzioti A, Kyritsis AP, Patsalos PN.
    Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
    Stockis A, Sargentini-Maier ML, Otoul C, Connor A, Wilding I, Wray H.
    Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
    [Abstract] [Full Text] [Related]

  • 33. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
    Sathe AG, Mishra U, Ivaturi V, Brundage RC, Cloyd JC, Elm JJ, Chamberlain JM, Silbergleit R, Kapur J, Lowenstein DH, Shinnar S, Cock HR, Fountain NB, Babcock L, Coles LD.
    J Clin Pharmacol; 2021 Jun; 61(6):763-768. PubMed ID: 33336359
    [Abstract] [Full Text] [Related]

  • 34. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials.
    Perucca E, Gidal BE, Baltès E.
    Epilepsy Res; 2003 Feb; 53(1-2):47-56. PubMed ID: 12576167
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
    Ji-qun C, Ishihara K, Nagayama T, Serikawa T, Sasa M.
    Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.
    Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS.
    Clin Pharmacokinet; 2005 Sep; 44(5):517-23. PubMed ID: 15871637
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model.
    Metcalf CS, Klein BD, Smith MD, Ceusters M, Lavreysen H, Pype S, Van Osselaer N, Twyman R, White HS.
    Epilepsia; 2018 Mar; 59(3):724-735. PubMed ID: 29360159
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.